PeerVoice Oncology & Haematology Audio
Health, Fitness & Longevity
About
PeerVoice is committed to producing and distributing evidence-based, independently-created medical education in Oncology & Haematology that is designed to positively impact patient care. Activities can either be accredited or non-accredited but are always driven by the learning and practice needs of healthcare professionals. Learn more at: https://peervoice.com.
Episodes
- Martin Köbel, MD - Scoring Folate Receptor-Alpha Expression in Gynecological Cancers: An Interactive Pathology Masterclass
For the complete activity, including supporting material, please visit https://www.peervoice.com/QYU860. Presented by Martin Köbel, MD and Diana N. Ionescu, MD, MSc (EMMP). Learning Objectives: Explain the staining pattern of FRα-positive…
- Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey
For the complete activity, including supporting material, please visit https://www.peervoice.com/RKZ860. Presented by Pier Luigi Zinzani, MD, PhD. Learning Objectives: Recall signs, symptoms, and outcomes associated with idiopathic multice…
- Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade
For the complete activity, including supporting material, please visit https://www.peervoice.com/FAN860. Presented by Austin Kulasekararaj, MD, MRCP, FRCPath; and Bruno Fattizzo, MD Learning Objectives: Discuss the criticality of achieving…
- Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era
For the complete activity, including supporting material, please visit https://www.peervoice.com/KBA860. Presented by Jonathan W. Goldman, MD and Misty Dawn Shields, MD, PhD. Learning Objectives: Recall the current evidence base and guidel…
- Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More
For the complete activity, including supporting material, please visit https://www.peervoice.com/AHU860. Presented by Matthew J. Koster, MD and Carmelo Gurnari, MD, PhD. Learning Objectives: Identify and distinguish the clinical presentati…
- Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?
For the complete activity, including supporting material, please visit https://www.peervoice.com/GNV860. Presented by Cristina Saura Manich, MD, PhD and Aditya Bardia, MD. Learning Objectives: Evaluate the clinical data for emerging therap…
- Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings
Visit https://www.peervoice.com/CCM860 to view the entire programme with slides. After completing “Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic…
- Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target
Visit https://www.peervoice.com/FCE860 to view the entire programme with slides. After completing “Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target”, participants…
- Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy
Visit https://www.peervoice.com/MQC860 to view the entire programme with slides. After completing “Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy”…
- Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025
Visit https://www.peervoice.com/USJ860 to view the entire programme with slides. After completing “Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025”, participants…
- Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO
Visit https://www.peervoice.com/YHE860 to view the entire programme with slides. After completing “Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO”, participan…
- Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC
Visit https://www.peervoice.com/XKC860 to view the entire programme with slides. After completing “Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC”,…
- Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies
Visit https://www.peervoice.com/EAJ860 to view the entire programme with slides. After completing “Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies”, par…
- Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NS…
- Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients
Visit https://www.peervoice.com/DHX860 to view the entire programme with slides. After completing “Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatm…
- Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease
Visit https://www.peervoice.com/RRA860 to view the entire programme with slides. After completing “Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease”, participants will be abl…
- Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?
Visit https://www.peervoice.com/TQR860 to view the entire programme with slides. After completing “Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?”, participants will be able to: R…
- Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making
Visit https://www.peervoice.com/EMZ860 to view the entire programme with slides. After completing “Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making”, participants will be able to:…
- Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer
Visit https://www.peervoice.com/GWG860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lun…
- Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients
Visit https://www.peervoice.com/BEZ860 to view the entire programme with slides. After completing “Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients”, participants w…
- Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer
Visit https://www.peervoice.com/DGN860 to view the entire programme with slides. After completing “Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of…
- Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer
Visit https://www.peervoice.com/HUF860 to view the entire programme with slides. After completing “Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care…
- Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy
Visit https://www.peervoice.com/SAU860 to view the entire programme with slides. After completing “Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy”, participants will be able to:…
- Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer
Visit https://www.peervoice.com/FKD860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer”, participants will…
- Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed
Visit https://www.peervoice.com/ZXH860 to view the entire programme with slides. After completing “Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease H…
- Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)
Visit https://www.peervoice.com/YZR860 to view the entire programme with slides. After completing “Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FN…
- Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
Visit https://www.peervoice.com/CFP860 to view the entire programme with slides. After completing “Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approach…
- Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma
Visit https://www.peervoice.com/QCE860 to view the entire programme with slides. After completing “Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma”, participants will be able to: Identify patients who may…
- Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions
Visit https://www.peervoice.com/JJY860 to view the entire programme with slides. After completing “Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Dec…
- Albrecht Stenzinger, MD - Optimising the Molecular Profiling Journey for Patients With CCA: Applying Best Practices and Avoiding Pitfalls
Visit https://www.peervoice.com/YDE860 to view the entire programme with slides. After completing “Albrecht Stenzinger, MD - Optimising the Molecular Profiling Journey for Patients With CCA: Applying Best Practices and Avoiding Pitfalls”,…
- Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC
Visit https://www.peervoice.com/YJY860 to view the entire programme with slides. After completing “Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC”, participants wi…
- Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?
Visit https://www.peervoice.com/DFF860 to view the entire programme with slides. After completing “Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?”, partici…
- Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer
Visit https://www.peervoice.com/YVF860 to view the entire programme with slides. After completing “Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Ca…
- John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis
Visit https://www.peervoice.com/TBB860 to view the entire programme with slides. After completing “John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cyto…
- Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours
Visit https://www.peervoice.com/KAX860 to view the entire programme with slides. After completing “Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours”, participants will be able to:…
- Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML
Visit https://www.peervoice.com/TUH860 to view the entire programme with slides. After completing “Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML”, participan…
- Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice
Visit https://www.peervoice.com/JQU860 to view the entire programme with slides. After completing “Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice”, pa…
- Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED
Visit https://www.peervoice.com/SYP860 to view the entire programme with slides. After completing “Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED”…
- Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts
Visit https://www.peervoice.com/CJQ860 to view the entire programme with slides. After completing “Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Ex…
- Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals
Visit https://www.peervoice.com/NXK860 to view the entire programme with slides. After completing “Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals”, partic…
- Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
Visit https://www.peervoice.com/QFE860 to view the entire programme with slides. After completing “Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences”, participants wil…
- Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
Visit https://www.peervoice.com/VCG860 to view the entire programme with slides. After completing “Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates”, participants will be…
- Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer
Visit https://www.peervoice.com/QWV860 to view the entire programme with slides. After completing “Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer”, partic…
- Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting
Visit https://www.peervoice.com/NFQ860 to view the entire programme with slides. After completing “Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting”, participant…
- Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes
Visit https://www.peervoice.com/SBN860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outco…
- Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events
Visit https://www.peervoice.com/FED860 to view the entire programme with slides. After completing “Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Eve…
- Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence
Visit https://www.peervoice.com/XJN860 to view the entire programme with slides. After completing “Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence”, p…
- Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
Visit https://www.peervoice.com/SKB860 to view the entire programme with slides. After completing “Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer”, participa…
- Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer
Visit https://www.peervoice.com/JQC860 to view the entire programme with slides. After completing “Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal C…
- Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem
Visit https://www.peervoice.com/NEQ860 to view the entire programme with slides. After completing “Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem”…